Orbus passes second bioequivalence test of generic Beloc-ZOK

By Angela McDaniels

Seattle, Sept. 7 - Orbus Pharma Inc. completed and passed the second of three bioequivalence studies it must undertake to demonstrate the therapeutic equivalence of its once-a-day formulation of metoprolol succinate 190 mg to the brand product, AstraZeneca plc's Beloc-ZOK (metoprolol CR/XL), according to a company news release.

Results of the third and final bioequivalence study are expected in the last quarter of 2006. If the study is successful, Orbus will license the product to North American and European companies for marketing and manufacturing.

Additionally, Orbus said it has a U.S. patent pending covering a propriety delivery system for the drug, which is a cardioselective beta-blocker for hypertension, angina pectoris, heart failure, disturbances of cardiac rhythm, functional heart disorders with palpitations and for migraine prophylaxis. AstraZeneca's Beloc-ZOK had reported sales of $1.735 billion for 2005.

Toronto-based Orbus Pharma licenses its generic drug developments in addition to manufacturing and selling pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.